FGFR2 and breast carcinoma: Polymorphisms in or near TOX3, LSP1, HCN1, MAP3K1 and at 2q35 are less strongly associated with breast cancer risk than polymorphisms in FGFR2; the increased risks range from 4% to 20% with each risk allele [8,9,16,24,25].